Overview
Jane Chao, PhD, is president, chief executive officer, co-founder, and director of Ceribell, a Sunnyvale medical technology company revolutionizing medical management of critically ill patients with AI-powered brain monitoring per its leadership page. Ceribell was founded in 2014 and builds a point-of-care electroencephalography platform for detecting and managing non-convulsive seizures in acute care settings.
The Ceribell System combines portable headband hardware with AI algorithms including Clarity for electrographic status epilepticus, designed to reduce hours-long delays typical of conventional EEG setup in ICUs and emergency departments.
Role and company
As President, CEO, Co-Founder, and Director, Chao leads Ceribell’s executive team including CTO Raymond Woo, PhD, CFO Scott Blumberg, and CRO Sean Manni per the leadership roster. Ceribell’s board includes co-founder Josef Parvizi, MD, PhD, and independent directors alongside Chao.
Chao is the quoted executive voice in major outcomes research releases, including a July 22, 2024 multi-center study associating Ceribell point-of-care EEG with shorter ICU length of stay versus conventional EEG.
Background and career context
Ceribell’s leadership page establishes Chao as co-founder, president, and CEO without listing prior employers on the cited page. She co-founded Ceribell in 2014 in Sunnyvale with Josef Parvizi, MD, PhD, who remains board co-founder per leadership disclosures.
Chao’s PhD credentials and CEO operating role combine scientific and commercial authority — a pattern common in medtech companies selling into ICU and emergency department buyers.
Company-building or leadership context
Under Chao’s leadership, Ceribell pursued FDA 510(k) clearance for Clarity AI algorithm for electrographic status epilepticus and CMS New Technology Add-on Payment (NTAP) per company press materials. Ceribell’s point-of-care model targets frontline EEG access where conventional EEG technician scheduling creates dangerous detection delays for non-convulsive status epilepticus.
Chao remains CEO through public company milestones and comparative outcomes publications building toward standard-of-care positioning for point-of-care EEG.
Public milestones
2014: Ceribell founded in Sunnyvale by Jane Chao and Josef Parvizi, MD, PhD. 2023: Clarity AI algorithm FDA 510(k) clearance and CMS NTAP awarded per company news. July 22, 2024: Multi-center study published associating Ceribell with 4.1 days shorter median ICU length of stay and 19 hours faster median time to EEG acquisition versus conventional EEG.
Chao is named president, CEO, co-founder, and director on ceribell.com leadership page reviewed July 10, 2026.
Why their work matters
Ceribell under Chao demonstrates that AI EEG at the point of care can change operational outcomes — ICU days and time-to-diagnosis — not merely provide algorithmic novelty. Non-convulsive seizures carry high morbidity when undetected; Chao’s platform addresses a workflow gap conventional EEG logistics cannot fill in busy emergency departments.
For healthcare AI readers, Ceribell is acute-care neurology AI distinct from ambulatory brain monitoring or psychiatric digital therapeutics.
Sources and references
Primary sourcing: Ceribell leadership team page, reviewed July 10, 2026.
- Ceribell — Leadership (ceribell.com)
Founded 2014 in Sunnyvale per leadership and press materials. ICU outcomes study from July 22, 2024 Ceribell release.
Ceribell leadership page lists executive team members Raymond Woo, PhD, as chief technology officer, Scott Blumberg as chief financial officer, and Sean Manni as chief revenue officer supporting Chao’s president and CEO role. Board co-founder Josef Parvizi, MD, PhD, remains director per leadership disclosures — maintaining scientific founder continuity alongside Chao’s operating executive authority.
July 2024 Ceribell outcomes research associating point-of-care EEG with 4.1 days shorter median ICU length of stay gives Chao hospital CFOs and chief nursing officers quantified operational ROI beyond seizure detection sensitivity alone — a buying criterion increasingly decisive in neurocritical care technology procurement.